IndivuTest will offer the Sysmex Inostics OncoBEAM test in Germany, Austria, and Switzerland under an exclusive distribution agreement.
The work could have implications not only for noninvasive prenatal testing, but also for oncology for detecting epigenetic changes in circulating tumor DNA.
CAPP Medical, based in Palo Alto, Calif., was founded in October 2013 by Stanford University oncologists and "industry veterans."
With the support of the new funds, the company hopes to launch its NeoLiquid test by the end of this year after completing beta tests.
Vendors and clinicians are struggling with how to deal with the growing number of cases of secondary findings from molecular non-invasive prenatal tests.
Management provided an update on reimbursement and new products in the works for whole-genome karyotyping, carrier screening, and oncology.
Sales of Illumina's HiSeq X Ten and NextSeq 500 instruments helped drive record revenues of $512.4 million in the fourth quarter of 2014.
Recent studies demonstrate that next-generation sequencing of ctDNA or CTCs can give a representative picture of a patient's tumor.
The assay could be useful for identifying patients unlikely to respond to therapy and provide an alternative for monitoring therapy response.
The test analyzes circulating cell-free DNA to gauge whether the patient is at high risk for prostate cancer and should go on to receive a biopsy.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.